Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Disease
83%
Neoplasm
80%
Chemotherapy
69%
Breast Cancer
56%
Malignant Neoplasm
50%
Cyclophosphamide
44%
Prostate Cancer
42%
Doxorubicin
42%
Placebo
42%
Mouse
40%
Melanoma
40%
Overall Survival
36%
Cisplatin
35%
Wheezing
34%
Clinical Trial
32%
Non Small Cell Lung Cancer
29%
Phase II Trials
26%
Metastatic Breast Cancer
25%
Symptom
25%
Prostate Carcinoma
22%
Progression Free Survival
21%
Etoposide
21%
Remission
20%
Imexon
19%
Pharmacokinetics
19%
Paclitaxel
18%
Prostate Specific Antigen
18%
Small Cell Lung Cancer
17%
Metastatic Melanoma
17%
Disease Free Survival
17%
Immunotherapy
15%
Colorectal Adenoma
15%
Recurrent Disease
15%
Solid Malignant Neoplasm
15%
Colon Cancer
14%
Denosumab
13%
Chronic Obstructive Lung Disease
13%
Bone Metastasis
13%
Metastasis
12%
Fluorouracil
12%
Biological Marker
12%
Myeloma
12%
Pancreas Cancer
11%
Mitomycin
11%
Lung Cancer
11%
Anticarcinogen
10%
Chemoradiation Therapy
10%
Dacarbazine
10%
Cytotoxicity
10%
Glutathione
10%
Tamoxifen
10%
Tumor Necrosis Factor
10%
Matrilysin
10%
Acute Leukemia
10%
Ipilimumab
10%
Adenoma
9%
Survival Rate
9%
Acute Myeloid Leukemia
9%
Zoledronic Acid
9%
Mycobacterium Bovis BCG
9%
Non-Steroidal Anti-Inflammatory Drug
9%
Perfosfamide
9%
Respiratory Tract
9%
Docetaxel
8%
Colorectal Cancer
8%
Vincristine
8%
Fluticasone
8%
Antitumor Activity
8%
Adverse Event
8%
Multiple Myeloma
8%
Gadolinium Pentetate
8%
Vinorelbine
8%
Bile Acid
8%
Integrin
7%
Infection
7%
Interleukin 2
7%
Drug Resistance
7%
Randomized Clinical Trial
7%
Group Trial
7%
Echo Contrast Medium
7%
Cohort Study
7%
Liposome
7%
Immunoglobulin E
7%
Atopy
6%
Neutropenia
6%
Interleukin 1
6%
Protein P53
6%
Carcinoma
6%
Acetylsalicylic Acid
6%
Clinical Study
6%
Letrozole
6%
Pembrolizumab
6%
Small Cell Carcinoma
6%
Disease Exacerbation
6%
Respiratory Tract Disease
6%
Androgen
6%
Allergen
6%
Hormone Receptor
5%
Eflornithine
5%
Medicine and Dentistry
Asthma
81%
Disease
70%
Neoplasm
52%
Breast Cancer
50%
Wheeze
46%
Prostate Cancer
44%
Oncology
44%
Malignant Neoplasm
34%
Nodular Melanoma
30%
Overall Survival
29%
Symptom
25%
Metastatic Carcinoma
24%
Placebo
24%
Childbirth
22%
Radiation Therapy
21%
Chronic Obstructive Pulmonary Disease
19%
Integrin
19%
In Vitro
19%
Clinical Trial
19%
Non Small Cell Lung Cancer
19%
Prostate Carcinoma
18%
Doxorubicin
18%
Respiratory Disease
18%
Small Cell Lung Cancer
17%
Magnetic Resonance Imaging
17%
Pediatrics
16%
Adenoma
16%
Cyclophosphamide
16%
Biological Marker
15%
Recurrent Disease
15%
Metastatic Breast Cancer
15%
Bone Marrow Transplantation
15%
Hazard Ratio
14%
Colorectal Adenoma
14%
Bone Metastasis
13%
Odds Ratio
13%
Tumor Cell
13%
Metastatic Melanoma
13%
Cisplatin
13%
Prostate Specific Antigen
12%
Progression Free Survival
12%
Acute Myeloid Leukemia
12%
Adjuvant Therapy
12%
Phase II Trials
11%
Transplantation
11%
Gene Expression
11%
Disease Free Survival
11%
Drug Megadose
11%
Biopsy
11%
Hematopoietic Stem Cell
11%
Protein P53
11%
Forced Expiratory Volume
11%
Autologous Bone Marrow Transplantation
10%
Colonoscopy
10%
Kalinin
10%
Lower Respiratory Tract
10%
Cohort Analysis
10%
Lymphocyte
10%
Immunotherapy
9%
Cell Transplantation
9%
Prognostic Factor
9%
Infection
9%
Sensitization
9%
Tamoxifen
9%
SCID Mouse
9%
Forced Vital Capacity
9%
Cancer Cell
9%
Adjuvant Chemotherapy
8%
Circulating Tumor Cell
8%
Acute Leukemia
8%
Dacarbazine
8%
Arm
8%
Etoposide
8%
Engraftment
8%
Group Trial
8%
Prostatic Intraepithelial Neoplasia
8%
Cell Line
8%
Leukocyte
8%
Infancy
7%
Epithelial Cell
7%
Positron Emission Tomography
7%
Immunohistochemistry
7%
Atopy
7%
Airflow
7%
Leukemia Cell
7%
Immunoglobulin E
7%
Extracellular Matrix
7%
Prematurity
7%
Denosumab
7%
Tumor Microenvironment
7%
Lung Function
7%
Cancer
7%
Lung Cancer
6%
Sarcoma
6%
Multiple Myeloma
6%
Chemoradiotherapy
6%
Randomized Clinical Trial
6%
Aromatase Inhibitor
6%
Drug Therapy
6%
Survival Rate
6%
Keyphrases
Asthma
64%
Southwest Oncology Group
27%
Wheezing
26%
Confidence Interval
17%
Chemotherapy
17%
Tumor
15%
Prostate Cancer
14%
Group Studies
14%
Metastatic Breast Cancer
14%
Lung Function
14%
Inhaled Corticosteroids
13%
Childhood Asthma
12%
Imexon
12%
Phase II Trial
12%
Overall Survival
12%
Colorectal Adenoma
11%
Cisplatin
10%
Human Prostate
10%
Lower Respiratory Tract Infection
10%
Randomized Trial
9%
Breast Cancer
9%
Placebo
9%
Allergy
9%
Lymphocytes
9%
Phase II Study
9%
Odds Ratio
8%
Denosumab
8%
Preschool children
8%
Tucson
8%
Melanoma
8%
Integrin
7%
AIDS/HIV
7%
Fluticasone Propionate
7%
Matrilysin
7%
Early childhood
7%
Chemoimmunotherapy
7%
Forced Expiratory Volume in 1 Second (FEV1)
7%
Hazard Ratio
7%
Selenium
7%
Prostate Carcinoma
7%
Atopy
7%
Bone Metastasis
7%
Remission
7%
Progression-free Survival
6%
Adult Life
6%
Tumor Necrosis Factor-α
6%
Soluble CD14 (sCD14)
6%
Polymorphism
6%
Clinical Trials
6%
Lipopolysaccharide
6%
Letrozole
6%
Pediatric Asthma
6%
Zoledronic Acid
6%
Disease-free Survival
6%
In Cancer
6%
Chronic Lymphocytic Leukemia
6%
Early Breast Cancer
6%
Small Cell Lung Cancer
6%
Cyclophosphamide
6%
Asthma Risk
6%
Response Rate
6%
Prostate
5%
Acute Leukemia
5%
First Year of Life
5%
Adenoma
5%
Non-small Cell Lung Cancer (NSCLC)
5%
Improved Outcomes
5%
IgE Levels
5%
Persistent Asthma
5%
Randomized Placebo-controlled Trial
5%
Total Prostate-specific Antigen
5%
Bone Marrow Transplantation
5%
Gene-environment Interaction
5%
Risk Factors
5%
Tumor Cells
5%
Allogeneic Bone Marrow Transplantation
5%
Lower Respiratory Illness
5%
Cancer Patients
5%
Asthma Prevalence
5%
Lung Cancer Treatment
5%
Natural History
5%
Asthma children
5%
Prostaglandin E2
5%
At Birth
5%
Randomized Controlled Trial
5%
Overexpression
5%
Airflow Limitation
5%
Aromatase Inhibitors
5%
Persistent Wheezing
5%
High Risk
5%
Leukemia
5%
CD14
5%